DNMT3A and hematologic disorder: Importantly, recently published data revealed that patients with hematological malignancies receiving allo-BMT from healthy donors harboring incidental DNMT3A mutations (most commonly loss-of-function) associated with asymptomatic clonal hematopoiesis of indeterminate potential (CHIP) have higher rates of chronic GVHD and lower risk of malignant relapse (14).